A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 May 2017 Planned End Date changed from 1 Jun 2019 to 3 Sep 2019.
- 01 May 2017 Planned primary completion date changed from 1 Jun 2019 to 20 Apr 2018.
- 01 May 2017 Status changed from not yet recruiting to recruiting.